Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Wednesday, July 26, 2017
 
Recommended for you
Perspectives: Too Often In U.S. Profit Comes Before Public Interest
Kaiser Health News
Democrats Announce Three-Pronged Plan To Tackle High Drug Prices
Kaiser Health News
Deep Dive: Health-care fund managers say a spike in drugs and devices will produce big returns
MarketWatch • Philipvan Doorn
The Startling History Behind Merck's New Cancer Blockbuster
Forbes • Contributor, David Shaywitz
Sienna Biopharmaceuticals Expected To IPO On Thursday
Seeking Alpha • Don Dion
ADMA Biologics Follows Up On RI-002
Seeking Alpha • Strong Bio
'Sparks' A-Flyin'
Seeking Alpha • Strong Bio
Our Unfounded Medical Optimism
Slate • Daniel Engber
Drug prices expected to rise 8% next year
Modern Healthcare • Alex Kacik
13 Remote Jobs You May Not Have Thought About
Forbes • Rachel Ritlop, Under 30
 
Recommended for You
Health Reform, Pharmaceuticals
Perspectives: Too Often In U.S. Profit Comes Before Public Interest
Kaiser Health News
Read recent commentaries about drug-cost issues.
Share
Gilead Sciences, GlaxoSmithKline plc
Democrats Announce Three-Pronged Plan To Tackle High Drug Prices
Kaiser Health News
News outlets report on stories related to pharmaceutical pricing.
Share
Finance, Health Care Industry
Deep Dive: Health-care fund managers say a spike in drugs and devices will produce big returns
MarketWatchPhilipvan Doorn
iStockphoto After last year’s underperformance, this seems to be a great time to invest in health-care stocks. The sector’s valuation is attractive, and the pace of drug approvals has increased. And even if the Republican-controlled Congress manages to “repeal and replace” the...
Share
Cancer, Health Care Industry
The Startling History Behind Merck's New Cancer Blockbuster
ForbesContributor, David Shaywitz
The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in...
Share
Biotechnology, Financial Regulatory Bodies
Sienna Biopharmaceuticals Expected To IPO On Thursday
Seeking AlphaDon Dion
Summary Sienna Biopharm is expected to make its market debut on 7.27, raising $65M. Focused on developing treatments for dermatological skin conditions, Sienna has three product candidates in clinical trials. The company has high spending needs and is years away from commercialization....
Share
Biotechnology, Epidemiology
ADMA Biologics Follows Up On RI-002
Seeking AlphaStrong Bio
Summary ADMA Biologics acquired assets of Biotest Pharmaceuticals, including two FDA approved antibody products, manufacturing facility, and cash funding commitment. ADMA is a contrarian investment candidate, trading at or near one year lows, as it works through regulatory FDA CRL manufacturing holds...
Share
Epidemiology, Health Finance
'Sparks' A-Flyin'
Seeking AlphaStrong Bio
Summary Lead candidate Luxterna could reach markets for biallelic RPE65-mediated inherited retinal disease in 2017, pending FDA review. The company is making headway in hemophilia B in early to mid-stage clinical trials for candidate SPK-9001, partnered with Pfizer. The company's partnership with...
Share
Epidemiology, Evidence-Based Medicine
Our Unfounded Medical Optimism
SlateDaniel Engber
Carl Court/Getty Images The parents of Charlie Gard announced on Monday that they’d given up on treating their 11-month-old child, who suffers from a rare and deadly gene mutation affecting his mitochondrial DNA. The roller-coaster case began in February when physicians at...
Share
Health Care Industry, Pharmaceuticals
Drug prices expected to rise 8% next year
Modern HealthcareAlex Kacik
Health systems can expect drug prices to increase by 7.61% next year, largely due to the surging prices of branded, specialty medications, a group purchasing organization said Tuesday. Vizient said in its drug pricing forecast that it's seen a spike in purchases...
Share
Pharmaceuticals, Recruiting
13 Remote Jobs You May Not Have Thought About
ForbesRachel Ritlop, Under 30
Telecommuting continues to grow in popularity across the US workforce. Millennials consider flexible work arrangements a top priority in overall job satisfaction. For those looking to achieve work-life balance and overall satisfaction, telecommuting may be a step in the right direction. One...
Share